Innovative Genetic Engineering
SL VaxiGen is R&D company dedicated to developing innovative vaccine therapeutics based on complementary platforms for saving lives.
Our goal is to save lives by various innovative genetic and protein engineering technologies especially for infectious diseases and cancers.
To become the leading global biotech company by developing innovative in-vivo gene therapeutics
To save and improve the quality of patient’s lives with intractable diseases
To induce antigen-specific strong and broad immunity, we combined the disease-specific multiple antigens and applied antigen engineering technologies such as codon optimization and gene shuffling in efficient expression vector system.
The adaptive immunity which is mainly composed of T cell and B cell (antibody) plays an crucial role in prevention and/or treatment of diseases. Thus, increasing the specific immune response to a certain pathogen is important for the development immunotherapeutic. BSA, bi-specific adaptive adjuvant, is designed for increasing antigen-specific (or vaccine-induced) adaptive immune responses by binding two or more targets in simultaneously.
We have identified multiple potential mechanistic application of the BSA platform, including the three described below,
|Category||Target Product||Indication||Development Stage|
|Infectious Diseases||SL-V10||CMV/BKV+ Transplantation|